IntelGenx (TSXV:IGX; OTCQX:IGXT) recently received the first shipment of cannabis extract from Tilray (NASDAQ:TLRY), providing it with sufficient quantities to commence batch production of cannabis-infused VersaFilm.
The supply of cannabis extract allows IntelGenx to advance development and production of cannabis-Infused VersaFilm products, marking an important milestone for the co-development program with Tilray.
Cannabis-infused VersaFilm products are intended to be launched as soon as reasonably possible after the October 17, 2019 implementation deadline for the Government of Canada’s Cannabis Act amendments that will authorize the sale of new classes of cannabis products, including extracts and edibles.
“IntelGenx remains the only company to have successfully established a Health Canada licensed and GMP compliant facility for pharmaceutical oral film manufacturing,” Horst Zerbe, CEO of IntelGenx, said in a statement.
“We believe that, in addition to enabling IntelGenx and our partner, Tilray, to offer cannabis products of the highest quality, this provides the companies with a valuable first-mover advantage in the space,” he added.
Woody Pastorius, chief revenue officer of Tilray, said that together with IntelGenx, “we are focused on innovation and delivering the best quality products to the market, as legislation allows.”
